---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-395694"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2026-09-18T21:00:21+00:00"
generated_at: "2026-09-18T21:02:33.026046+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Atossa updates corporate presentation on (Z)-Endoxifen, but no specifics disclosed

## Summary
- Filed updated corporate presentation on 8-K Sept 18, 2026; no financial or clinical data shown.
- Presentation cover cites (Z)-Endoxifen as potential best-in-class oral SERM/SERD for estrogen-driven diseases.
- Available exhibit excerpt contains only the title slide; operational milestones or guidance not provided.

## SEC filing metadata
- accession: 0001193125-26-395694
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2026-09-18T21:00:21+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312526395694/0001193125-26-395694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312526395694/atos-20260918.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-395694
- JSON: https://secwatch.observer/filing/0001193125-26-395694.json
- Plain text: https://secwatch.observer/filing/0001193125-26-395694.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.